Esma SARIKAYA, Özlem Gün ERYILMAZ, ŞENOL BOZDAĞ, Rüya DEVEER, Şerife OGUZ SUNA, Uğur DİLMEN

Maternal characteristics and perinatal outcome of babies born with isolated congenital ichthyosis: 3 Years of experience in a medical center

Amaç: Bu çalışmada amacımız izole konjenital ihtiyoz ile doğmuş bebeklerin perinatal sonuçları ile maternal karakteristiklerini özellikle maternal hastalıklar ve kullan-dıkları ilaçlar açısından ele almak ve konjenital ihtiyoz oranımızı belirlemekti. Materyal ve Metot: Zekai Tahir Burak Kadın Hastalık-ları Eğitim ve Araştırma Hastanesi’nde konjenital ihtiyoz ile doğmuş bebeklerin maternal karakteristikleri ve neonatal sonuçlarının tek merkezli prospektif/retrospektif kesitsel analizi. Bulgular: Üç yıllık konjenital ihtiyoz oranımız 1/10806 idi. Konjenital ihtiyoz vakalarının %50’sinde maternal ilaç kullanım hikayesi vardı. Sonuç: Annenin özellikle otoimün hastalıkları ve bunlar için kullanılan ilaçların yenidoğanda kütanöz yan etkilere ve belki de edinsel ihtiyoza sebep olabileceği unutulma-malıdır.

Anahtar Kelimeler:

Doğumsal anormallikler, Geriyedönük çalışma, Gebelik sonucu, İleriye dönük çalışma, İktiyozis

İzole konjenital ihtiyoz ile doğmuş bebeklerin maternal karakteristikleri ve perinatal sonuçlar:3 yıllık tecrübemiz

Background: Our purpose was to determine the perinatal outcome and maternal characteristics of babies born with isolated congenital ichthyosis with special emphasis on maternal diseases and medications used for them and to determine our congenital ichthyosis rate. Material and Method: Single center retrospective/ prospective cross-sectional analysis of maternal characteristics and neonatal outcome variables of babies born with ichthyosis in Zekai Tahir Burak Women's Health Research and Education Hospital, Ankara, Turkey. Results: Our three year congenital ichthyosis rate was 1/10806. In 50% of congenital ichthyosis cases there was history of maternal drug intake. Conclusions: It must be kept in mind that; medical conditions of the mother especially autoimmune ones and medications used for them could lead to a variety of cutaneous side affects and possibly acquired ichthyosis of the newborn.

Keywords:

Congenital Abnormalities, Retrospective Studies, Pregnancy Outcome, Prospective Studies, Ichthyosis,

PDF

___

1. Shwayder T. Disorders of keratinization: diagnosis and management. Am J Clin Dermatol 2004;5(1):17-29.
2. Oji V, Traupe H. Ichthyoses: differential diagnosis and molecular genetics. Eur J Dermatol 2006;16(4):349-59.
3. Oji V, Tadini G, Akiyama M, Blanchet Bardon C, Bodemer C, Bourrat E, et al. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol 2010;63(4):607-41.
4. Krug M, Oji V, Traupe H, Berneburg M. Ichthyoses-Part 2: Congenital ichthyoses. J Dtsch Dermatol Ges 2009;7(7):577-88.
5. Gånemo A, Pigg M, Virtanen M, Kukk T, Raudsepp H, Rossman-Ringdahl I, et al. Autosomal recessive congenital ichthyosis in Sweden and Estonia: clinical, genetic and ultrastructural findings in eighty-three patients. Acta Derm Venereol 2003;83(1):24-30.
6. Vahlquist A, Ganemo A, Pigg M, Virtanen M, Westermark P. The clinical spectrum of congenital ichthyosis in Sweden: a review of 127 cases. Acta Derm Venereol Suppl (Stockh) 2003;(213):34-47.
7. Kharfi M, El Fekih N, Ammar D, Khaled A, Fazaa B, Ridha Kamoun M. Hereditary ichthyosis in Tunisia: epidemiological study of 60 cases. Tunis Med 2008;86(11):983-6.
8. Rajpopat S, Moss C, Mellerio J, Vahlquist A, Gånemo A, Hellstrom-Pigg M, et al. Harlequin ichthyosis: a review of clinical and molecular findings in 45 cases. Arch Dermatol 2011;147(6):681-6.
9. Van Gysel D, Lijnen RL, Moekti SS, de Laat PC, Oranje AP. Collodion baby: a follow-up study of 17 cases. J Eur Acad Dermatol Venereol 2002;16(5):472-5.
10. Vahlquist A. Pleomorphic ichthyosis: proposed name for a heterogeneous group of congenital ichthyoses with phenotypic shifting and mild residual scaling. Acta Derm Venereol 2010;90(5):454-60.
11. Patel N, Spencer LA, English JC 3rd, Zirwas MJ. Acquired ichthyosis. J Am Acad Dermatol 2006;55(4):647-56.
12. Sanli H, Akay BN, Sen BB, Kocak AY, Emral R, Bostanci S. Acquired ichthyosis associated with type 1 diabetes mellitus. Dermatoendocrinol 2009;1(1):34-6.
13. Nenna R, D'Eufemia P, Celli M, Mennini M, Petrarca L, Zambrano A, et al. Celiac disease and lamellar ichthyosis. Case study analysis and review of the literature. Acta Dermatovenerol Croat 2011;19(4):268-70.
14. Kurtoğlu S, Caksen H, Erdoğan R, Kisaarslan AF. Collodion baby concomitant with congenital hypothyroidism: a patient report and review of the literature. J Pediatr Endocrinol Metab 1998;11(4):569-73.
15. Dogan DG, Aslan M, Karabiber H. A collodion baby with hypothyroidism. Genet Couns 2010;21(3):343-6.
16. Vahlquist A, Gånemo A, Virtanen M. Congenital ichthyosis: an overview of current and emerging therapies. Acta Derm Venereol 2008;88 (1):4-14.
17. Akiyama M, Sugiyama-Nakagiri Y, Sakai K, McMillan JR, Goto M, Arita K, et al. Mutations in lipid transporter ABCA12 in harlequin ichthyosis and functional recovery by corrective gene transfer. J Clin Invest 2005;115 (7):1777-84.
18. O'Shaughnessy RF, Choudhary I, Harper JI. Interleukin-1 alpha blockade prevents hyperkeratosis in an in vitro model of lamellar ichthyosis. Hum Mol Genet 2010;19(13):2594-605.
19. Oji V, Traupe H. Ichthyosis: clinical manifestations and practical treatment options. Am J Clin Dermatol 2009;10(6):351-64.
20. Chan YC, Tay YK, Tan LK, Happle R, Giam YC. Harlequin ichthyosis in association with hypothyroidism and juvenile rheumatoid arthritis. Pediatr Dermatol 2003;20(5):421-6.
21. Shulman AI, Mangelsdorf DJ Retinoid X receptor heterodimers in the metabolic syndrome. N Engl J Med 2005;353: 604–15.
22. Huq MD, Tsai NP, Gupta P, Wei LN. Regulation of retinal dehydrogenases and retinoic acid synthesis by cholesterol metabolites. EMBO J 2006;25(13):3203-13.
23. Cagen LM, Deng X, Wilcox HG, Park EA, Raghow R, Elam MB. Insulin activates the rat sterol-regulatory-element-binding protein 1c (SREBP-1c) promoter through the combinatorial actions of SREBP, LXR, Sp-1 and NF-Y cis-acting elements. Biochem J 2005;385(Pt 1):207-16.
24. Yosipovitch G, Hodak E, Vardi P, Shraga I, Karp M, Sprecher E, et al. The prevalence of cutaneous manifestations in IDDM patients and their association with diabetes risk factors and microvascular complications. Diabetes Care 1998;21(4):506-9.
25. O'Kane M, Murphy EP, Kirby B. The role of corticotropin-releasing hormone in immune-mediated cutaneous inflammatory disease. Exp Dermatol 2006;15(3):143-53.
26. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002;360(9340):1155–62.
27. Burman KD, McKinley-Grant L. Dermatologic aspects of thyroid disease. Clin Dermatol 2006;24(4):247–55.
28. Cianfarani F, Baldini E, Cavalli A, Marchioni E, Lembo L, Teson M, et al. TSH receptor and thyroid-specific gene expression in human skin. J Invest Dermatol 2010;130(1):93–101.
29. Dix JH, Levy WJ, Fuenning C. Remission of acanthosis nigricans, hypertrichosis, and Hashimoto's thyroiditis with thyroxine replacement. Pediatr Dermatol 1986;3(4):323-6.
30. Brazzelli V, Larizza D, Muzio F, Fornara L, Calcaterra V, Vassallo C, et al. Acquired ichthyosis in a child with autoimmune thyroiditis. Pediatr Dermatol 2010;27(4):413-4.
31. Brazzelli V, Prestinari F, Barbagallo T, Bellani E, Calcaterra V, Larizza D, et al. Acquired ichthyosis and hypertrichosis due to autoimmune thyroiditis: therapeutic response to thyroxine replacement. Pediatr Dermatol 2005;22(5):447-9.
32. Lafranchi S. Thyroiditis and acquired hypothyroidism. Pediatr Ann 1992;21(1):29, 32-9.
33. Aloush V, Litinsky I, Caspi D, Elkayam O. Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management. Semin Arthritis Rheum 2006;36(1):4-9.
34. Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, et al. Skin collagen glycation, glycoxidation and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type I diabetes: Relevance of glycated collagen products versus HbA 1c as markers of diabetic complications. Diabetes 1999;48(4):870-80.
35. Yetgin S, Aytaç S, Olcay L, Tunç B, Ozbek N, Aydinok Y. Evaluation of the effects of and earliest response rate to anti-D treatment in children with chronic idiopathic thrombocytopenic purpura: a pilot study. Turk J Pediatr 2010;52(2):126-31.